Home » Teva Receives Favorable Court Decision Regarding Generic Famvir
Teva Receives Favorable Court Decision Regarding Generic Famvir
Teva Pharmaceutical Industries announced that the U.S. District Court For the District of New Jersey has denied a motion filed by Novartis for a preliminary injunction related to Teva’s famciclovir tablets, a generic version of Novartis’ herpes treatment Famvir.
Teva’s abbreviated new drug application to market its famciclovir in 125-, 250- and 500-mg strengths has already been granted final approval by the FDA.
The brand product had annual U.S. sales of approximately $200 million for the twelve months ending June 30, based on IMS sales data.
Teva is currently involved in patent litigation with Novartis concerning this product. A trial date has not been set.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May